

Pharmacy therapeutic area trends

Therapeutic area trends reinforce the importance of evaluating pharmacy spend through both price and utilization lenses.

Purchases and estimated price changes by therapeutic area, January 2027–December 2027

Therapeutic area	Disease state(s)	Top products by spend	Estimated price change	Vizient Pharmacy Program participant purchases
Autoimmune and inflammatory conditions	Dermatology, gastroenterology, rheumatology	Skyrizi, Dupixent, Humira, Enbrel	4.10%	23.39%
Cardiopulmonary conditions	Asthma, cardiology, COPD, pulmonary hypertension	Vyndamax, Xolair, Trikafta	3.45%	4.81%
Endocrine and metabolic diseases	Diabetes, obesity, osteoporosis	Mounjaro, Ozempic, Jardiance, Prolia	2.04%	11.73%
Hematological	Bleeding disorders, clotting disorders, growth factors	Eliquis, Activase, Ultomiris, TNKase	2.66%	6.57%
Infectious diseases	COVID-19, HIV, vaccinations	Biktarvy, Prevnar-20, Gardasil	4.62%	11.18%
Neurology	Epilepsy, movement disorders, multiple sclerosis	Ocrevus, Botox, Kesimpta, Nurtec ODT	2.99%	5.40%
Oncology	Leukemia, lymphoma, solid tumors	Keytruda, Darzalex Faspro, Opdivo, Imfinzi	4.14%	25.59%
Plasma	Critical care, immune-mediated disorders, oncology	Albumin; Immune globulin	2.92%	3.92%

Source: Vizient Pharmacy Program participant data, April 2025–March 2026

Abbreviations: COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus; ODT = orally disintegrating tablet

Learn more about how these category movements connect to broader trends by visiting the [Spend Management Outlook](#).

Vizient, Inc. provides solutions and services that improve the delivery of high-value care by improving financial sustainability, system performance, and accelerating strategic growth for more than two-thirds of the nation's healthcare providers. Vizient provides expertise, analytics, consulting services, and a contract portfolio representing \$156 billion in annual client purchasing volume to improve patient outcomes and lower costs. vizient.com